UTILX Corporation Announces an Extension of an Exclusive Licensing Arrangement with Thomas &Betts.

Business Editors/Technology Writers

KENT, Wash.--(BUSINESS WIRE)--Feb. 7, 2000

UTILX Corporation (Nasdaq:UTLX) announced that it has executed an amendment to its exclusive license agreement with the Elastimold unit of Thomas &Betts (T&, Memphis, TN) for the manufacture and distribution of fluid injection caps. The agreement leaves T& as the exclusive manufacturer and UTILX as the exclusive distributor. The caps are a critical component in the delivery of UTILX's CableCURE(R) fluid treatment to improve the reliability of power cables. T& along with Dow Corning Corporation patented the fluid injection cap eight years ago. The amendment extends UTILX's worldwide exclusivity to use and distribute the patented technology through the patent expiration date in 2009.

&uot;Without the fluid injection cap technology,&uot; said William M. Weisfield, President and CEO of UTILX Corporation, &uot;there would be a considerable economic and operational penalty. UTILX and our strategic partners including Dow Corning and Thomas &Betts have invested heavily in the creation of a unique portfolio of intellectual property. That portfolio has served us well as there have been no other entries in our market niche for the 13 years since CableCURE(R) was first commercialized. We are pleased to extend our exclusive relationship with T& at least until our jointly developed patent expires.&uot;

UTILX holds the exclusive license on 10 patents from Dow Corning Corporation (Midland, Michigan) and holds other independent patents and is pursuing several more in various phases of the application process. There are no known direct commercial competitors to UTILX's CableCURE(R) injection process. CableCURE(R) treatment typically cost less than one-half of the cost to replace cable and restores the old cable reliability to that expected of new cables. Over the 13 years of field experience, CableCURE(R) treatment has demonstrated 99.5% reliability.

UTILX Corporation provides critical services for the installation and rejuvenation of aged underground infrastructure with its FlowMOLE(R) service and proprietary CableCURE(R) solution in the U.S. and Canada through a network of regional sales and service centers. The Company also provides CableCURE(R) services throughout Europe and Asia.

This release contains forward-looking statements relating to the Company's existing and future products and services and future operating results that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words &uot;believe&uot;, &uot;expect&uot;, &uot;intend&uot;, &uot;plan&uot;, variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Reference is made to the Company's latest Annual Report on Form 10-K filed with the SEC for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.